Research shows benefit of dapagliflozin for heart failure patients regardless of ejection fraction
Dapagliflozin reduces the risks of death and cardiovascular events in patients with heart failure, regardless of ejection fraction, according to late-breaking research presented today at a Hot Line session at ESC Congress 2022. This pre-specified patient-level meta-analysis combined the DAPA-HF and DELIVER trials of the SGLT2 inhibitor dapagliflozin in patients with heart failure. DAPA-HF enrolled … Read more